This report describes the case of a 71-year-old woman with a limited form of neuromyelitis optica (NMO) who had a longitudinally extensive spinal cord lesion from the fourth to the tenth thoracic vertebrae.
Background: Neuromyelitis optica (NMO) frequently begins with a monofocal episode of optic neuritis or myelitis. A concept named high-risk syndrome (HRS) for NMO has been proposed for patients with monofocal episodes and NMO-IgG antibodies. Objective: To describe HRS patients and compare them with NMO patients
OBJECTIVE: To evaluate the efficacy and safety of mitoxantrone hydrochloride and determine how it exhibits a differential inhibitory effect on subsets of B cells in patients with highly relapsing neuromyelitis optica (NMO).
Neuromyelitis optica is a central nervous system disease characterized by optic neuritis and transverse myelitis. It is a devastating illness, and early treatment may prevent future relapses and severe disability. However, there is much variability in protocols used for treatment.
Neuromyelitis optica (NMO) is an inflammatory/demyelinating disorder predominantly affecting the optic nerves and spinal cord. Recent findings showed an underlying humoral abnormality in NMO, characterized by a serum antibody against aquaporin-4 (Aqp-4-Ab). In this study, we evaluated the Aqp-4-Ab status among Turkish patients with NMO to determine the clinical and prognostic relevance
OBJECTIVE: To investigate the differential diagnostic value of NMO-IgG for neuromyelitis optica (NMO) versus multiple sclerosis (MS) and to analyze its possible clinical features related to NMO-IgG. METHODS: Forty-one NMO patients and 44 MS patients in acute phase and 40 healthy controls were investigated. Serum NMO-IgG was tested by indirect immunofluorescence assay.
Background: Although brain lesions are now recognized more frequently in neuromyelitis optica spectrum disorder (NMOSD), most of them have been reported to be nonspecific and rarely symptomatic.
Background: Recurrent myelitis (rM) represents a pathogenetically heterogeneous group of inflammatory diseases with a selective involvement of the spinal cord. The recent description of NMO Ig-G antibody, the specific biomarker for Neuromyelites Optica (NMO), also in patients with recurrent myelitis with longitudinally extensive transverse spinal cord lesions (LETM), has brought to consider this disease an incomplete form of NMO (NMO Spectrum of Disorders). Methods: we retrospectively selected patients (pts) with rM attended our neurological department between January 2000 and March 2010
Background: Neuromyelitis optica (NMO) is an inflammatory disease associating optic neuritis and myelitis. Recently, several works showed that optical coherence tomography (OCT) should be an interesting method of disease severity.
Background: Using an anti-aquaporin-4 (AQP4) antibody assay discovered in 2005, Japanese patients with neuromyelitis optica (NMO) can easily be differentially diagnosed from those with opticospinal multiple sclerosis (MS).
Background: Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system (CNS) associated with a specific autoantibody, anti-aquaporin-4 antibody (AQP4-Ab). Although low-dose corticosteroids and immunosuppressants are widely used for prevention in NMO, the efficacy is not yet confirmed by large controlled studies. Objective: To evaluate the benefit of low-dose prednisolone therapy in patients with relapsing NMO.
OBJECTIVE: To evaluate serum and cerebrospinal fluid (CSF) NAA concentrations in patients with different demyelinating disease phenotypes and to correlate them with clinical measures. BACKGROUND: NAA is considered a marker of the functional integrity of neuronal mitochondrial metabolism that is mainly catabolised in oligodendrocytes. Normal appearing white matter (NAWM) damage, reported in MS but not in NMO by MRI studies, is associated with decreased brain NAA levels.